GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Xcorporeal Inc (GREY:XCRP) » Definitions » Debt-to-EBITDA

Xcorporeal (Xcorporeal) Debt-to-EBITDA : 0.00 (As of Sep. 2009)


View and export this data going back to . Start your Free Trial

What is Xcorporeal Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Xcorporeal's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2009 was $0.00 Mil. Xcorporeal's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2009 was $0.00 Mil. Xcorporeal's annualized EBITDA for the quarter that ended in Sep. 2009 was $-6.04 Mil. Xcorporeal's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2009 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Xcorporeal's Debt-to-EBITDA or its related term are showing as below:

XCRP's Debt-to-EBITDA is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 1.25
* Ranked among companies with meaningful Debt-to-EBITDA only.

Xcorporeal Debt-to-EBITDA Historical Data

The historical data trend for Xcorporeal's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Xcorporeal Debt-to-EBITDA Chart

Xcorporeal Annual Data
Trend Feb99 Feb00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -20.15 -58.18 - - -

Xcorporeal Quarterly Data
Dec04 Mar05 Jun05 Sep05 Dec05 Mar06 Jun06 Sep06 Dec06 Mar07 Jun07 Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Xcorporeal's Debt-to-EBITDA

For the Medical Devices subindustry, Xcorporeal's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xcorporeal's Debt-to-EBITDA Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xcorporeal's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Xcorporeal's Debt-to-EBITDA falls into.



Xcorporeal Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Xcorporeal's Debt-to-EBITDA for the fiscal year that ended in Dec. 2008 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -31.788
=0.00

Xcorporeal's annualized Debt-to-EBITDA for the quarter that ended in Sep. 2009 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -6.044
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Sep. 2009) EBITDA data.


Xcorporeal  (GREY:XCRP) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Xcorporeal Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Xcorporeal's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Xcorporeal (Xcorporeal) Business Description

Traded in Other Exchanges
N/A
Address
80 Empire Drive, Lake Forest, CA, USA, 92630
Website
Xcorporeal Inc is a medical device company, developing an innovative extra-corporeal platform technology to be used in devices to replace the function of various human organs.
Executives
Kelly J. Mccrann director, officer: Chairman and CEO 11150 SANTA MONICA BLVD #1500, LOS ANGELES CA 90025
Daniel S Goldberger officer: Chief Executive Officer 24 CARPENTER ROAD, CHESTER NY 10918
Marc G Cummins director C/O PRIME LOGIC CAPITAL, LLC, 135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Prime Logic Capital, Llc 10 percent owner 135 EAST 57TH STREET, 11TH FLOOR, NEW YORK NY 10022
Robert Weinstein officer: Chief Financial Officer 3960 HOWARD HUGHES PARKWAY, SUITE 500, LAS VEGAS NV 89169
Terren S Peizer director, 10 percent owner, officer: Executive Chairman 11111 SANTA MONICABLVD STE.500, LOS ANGELES CA 90025
Jay Wolf director 981 LINDA FLORA DRIVE, LOS ANGELES, CA 90049
Herve De Kergrohen director 22 CHEMIN DU NANTET, COLLONGE-BELLERIVE V8 CH1245
Nicholas Sheridan Lewin director 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Lawrence Lacerte 10 percent owner C/O TERAGLOBAL COMMUNICATIONS CORP, 9171 TOWNE CENTRE DRIVE SUITE 600, SAN DIEGO CA 92122

Xcorporeal (Xcorporeal) Headlines